Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting.

Autor:	López-Lacort M; Vaccine Research Department, Fisabio-Public Health, Valencia, Spain.; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain.; Contributed equally as co-first authors., Muñoz-Quiles C; Vaccine Research Department, Fisabio-Public Health, Valencia, Spain.; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain.; Contributed equally as co-first authors., Mira-Iglesias A; Vaccine Research Department, Fisabio-Public Health, Valencia, Spain.; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain., López-Labrador FX; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain.; Virology Laboratory, Fisabio-Public Health, Valencia, Spain.; Department of Microbiology and Ecology, Medical School, University of Valencia, Valencia, Spain., Garcés-Sánchez M; Nazaret Health Center, Clinic Hospital-Malvarrosa Department, Valencia, Spain., Escribano-López B; Vaccine Research Department, Fisabio-Public Health, Valencia, Spain., Zornoza-Moreno M; Murcia Health Council, Murcia, Spain., Pérez-Martín JJ; Murcia Health Council, Murcia, Spain., Alfayate-Miguelez S; Murcia Health Council, Murcia, Spain., Iofrío-De Arce A; Centro de Salud El Ranero, Murcia, Spain., Pastor-Villalba E; Dirección General de Salud Pública, Valencia, Spain., Lluch-Rodrigo JA; Dirección General de Salud Pública, Valencia, Spain., Díez-Domingo J; Vaccine Research Department, Fisabio-Public Health, Valencia, Spain.; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain.; Catholic University of Valencia, Valencia, Spain., Orrico-Sánchez A; Vaccine Research Department, Fisabio-Public Health, Valencia, Spain.; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain.; Catholic University of Valencia, Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Pediatrics [Pediatrics] 2024 Oct 04. Date of Electronic Publication: 2024 Oct 04.
DOI:	10.1542/peds.2024-066393
Abstrakt:	Objectives: This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTI) in a large primary care network in Spain, in both overall and catch-up infants under ten months of age. Methods: The 2023-24 immunization campaign with nirsevimab in Spain targeted all infants born after April 1st, 2023. Those born after October 1st received it at birth in hospitals, while others received it through a catch-up program. The MEDIPRIM network of primary care centers recruited all infants with LRTI for RSV PCR testing and employed a test-negative design (TND) approach to estimate the effectiveness of nirsevimab. Results: The study included 160 infants, 141 (88%) of them received nirsevimab and 128 belonged to the catch-up group (88% received nirsevimab). Overall, RSV was detected in 44 infants (27.5%). Within the catch-up group, 37 (28.9%) were positive for RSV. The overall effectiveness was 75.8% (95% CI: 40.4-92.7), and 80.2% (95% CI: 44.3-95.4) in infants belonging to the catch-up group. Conclusions: This study underscores the effectiveness of nirsevimab in preventing medically attended LRTI in infants in outpatient settings and emphasizes the importance of a catch-up immunization program to reduce the disease burden in primary care. Competing Interests: CONFLICT OF INTEREST DISCLOSURES: Cintia Muñoz-Quiles, Mónica López-Lacort, Javier Díez-Domingo, and Alejandro Orrico-Sánchez have attended several congresses, whose registration, travel, and accommodation costs covered by MSD, GSK, AZ, and SP. Alejandro Orrico-Sánchez and Javier Díez-Domingo, along with their institution, have received research grants from SP, GSK and AZ for studies unrelated to this one. Alejandro Orrico-Sánchez and Javier Díez-Domingo have acted as advisors for this immunization strategy to SP, with Alejandro Orrico-Sánchez also advising Moderna. Ainara Mira-Iglesias has received fees for conferences/experts’ meetings from SP and for educational events from MSD. F. Xavier López-Labrador has received funding from SP and Merck for studies unrelated to this one. Antonio Iofrío-De Arce has collaborated in educational activities supported by AZ, GSK, MSD and Pfizer, and as a consultant on the Advisory Board of GSK and Pfizer. He has received support from GSK, MSD and Pfizer to attend national educational activities. Matilde Zornoza-Moreno has collaborated in teaching activities funded by AZ, GSK and MSD, and as a consultant on the Advisory Board of MSD. She has received support from GSK, Seqirus, AZ, MSD and Pfizer to attend national and international teaching activities. María Garcés-Sánchez has received honoraria from GSK group of companies, Pfizer, Sanofi and MSD, for taking part in advisory boards and experts’ meetings and for acting as a speaker in congresses outside the scope of the submitted work. Jaime Jesús Pérez-Martín has received support for teaching activities from AZ, GSK, Pfizer and MSD, and as a consultant on the Advisory Board of MSD, Sanofi and Moderna. He has received support from GSK, Seqirus, AZ, GSK, MSD and Pfizer to attend national and international teaching activities. Santiago Alfayate-Miguelez has received support to attend teaching activities from Pfizer and MSD. Eliseo Pastor-Villalba has collaborated in educational activities whose registration, travel, and accommodation costs were covered by GSK, Seqirus, AZ, MSD and Pfizer. Other authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu